Dealing Biogen another blow, EMA recommends rejecting Aduhelm in three terse paragraphs
The European Medicines Agency announced Friday it recommended the European Commission reject Aduhelm, dealing a new — albeit expected — blow to Biogen’s hopes of finding a widespread market for its struggling Alzheimer’s drug.
The EMA recommendation had been expected for a month, since the EMA’s human medicines committee gave Biogen “a negative trend vote” after an oral presentation from the company. As such Biogen’s stock, which has lost all the stratospheric value it gained after Aduhelm’s approval in June, only ticked down 3% pre-market Friday, from $235.52 to $235.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.